CEBPG

Across TCGA pan-cancer cohorts, CEBPG mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CEBPG data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CEBPG mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CEBPG expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where CEBPG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.644	0.898	.011	9	view →
HNSC	DFS	Median	II,III,IV	1.000	0.807	.019	7	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.244	.024	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CEBPG–LSCC (OS)

Open the LSCC breakdown →